Intracoronary GP IIb/IIIa Inhibitors: Could Eptifibatide Be the New Kid on the Block?

Publisher： Karger

E-ISSN： 1421-9751|123|1|43-45

ISSN： 0008-6312

Source： Cardiology, Vol.123, Iss.1, 2012-09, pp. : 43-45

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Combination pharmacotherapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa inhibition

By Bush H.S.  

Journal of Emergency Medicine, Vol. 25, Iss. 4, 2003-11 ,pp. : 421-426

Elsevier

Access to resources Recommend Favorite

Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 3, 2015-09 ,pp. : 390-396

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of Glycoprotein IIb/IIIa Inhibitors in Patients with Acute Coronary Syndromes Undergoing Coronary Revascularization

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 29, Iss. 1, 2004-11 ,pp. : 69-71

Karger

Access to resources Recommend Favorite

The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes

By Bolognese Leonardo  

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1217-1226

Informa Healthcare

Access to resources Recommend Favorite

Hepatitis E: The ‘New Kid on the Block' or an Old Friend?

By  

Transfusion Medicine and Hemotherapy, Vol. 41, Iss. 1, 2014-02 ,pp. : 6-9

Karger

Access to resources Recommend Favorite